ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human
polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

Physical activity provides clinical benefit in Parkinson's disease (PD). Irisin is an exercise-
induced polypeptide secreted by skeletal muscle that crosses the blood–brain barrier and …

Abstract Background Dementia with Lewy bodies (DLB) and Parkinson's disease dementia
(PDD), which share many clinical, neurochemical, and morphological features, have been …

Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …

Background Common genetic variance in apolipoprotein E (APOE), β‐glucocerebrosidase
(GBA), microtubule‐associated protein tau (MAPT), and α‐synuclein (SNCA) has been …

The complex nature of human cognition has resulted in cognitive genomics lagging behind
many other fields in terms of gene discovery using genome-wide association study (GWAS) …

Background There are currently no treatments that stop or slow the progression of
Parkinson's disease (PD). Case–control genome‐wide association studies have identified …

Importance Parkinson disease (PD) is heterogeneous in symptom manifestation and rate of
progression. Identifying factors that influence disease progression could provide …

People with Parkinson's disease (PD) and their care partners frequently report cognitive
decline as one of their greatest concerns. Mild cognitive impairment affects approximately 20 …